Related Experiment Video
Updated: May 31, 2025
Author Spotlight: Exploring Strategies for Successful Immune Response Against Tumors
Published on: August 16, 2024
Integrated cancer cell-specific single-cell RNA-seq datasets of immune checkpoint blockade-treated patients
Mahnoor N Gondal1,2, Marcin Cieslik3,4,5,6, Arul M Chinnaiyan7,8,9,10,11,12
1Department of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, MI, USA.
Abstract:
Immune checkpoint blockade (ICB) therapies have emerged as a promising avenue for the treatment of various cancers. Despite their success, the efficacy of these treatments is variable across patients and cancer types. Numerous single-cell RNA-sequencing (scRNA-seq) studies have been conducted to unravel cell-specific responses to ICB treatment. However, these studies are limited in their sample sizes and require advanced coding skills for exploration. Here, we have compiled eight scRNA-seq datasets from nine cancer types, encompassing 223 patients, 90,270 cancer cells, and 265,671 other cell types. This compilation forms a unique resource tailored to investigate how cancer cells respond to ICB treatment across cancer types. We meticulously curated, quality-checked, pre-processed, and analyzed the data, ensuring easy access for researchers. Moreover, we designed a user-friendly interface for seamless exploration. By sharing the code and data for creating these interfaces, we aim to assist fellow researchers. These resources offer valuable support to those interested in leveraging and exploring single-cell datasets across diverse cancer types, facilitating a comprehensive understanding of ICB responses.
Insights
This study compiles single-cell RNA sequencing data from nine cancer types to explore immune checkpoint blockade (ICB) responses. The accessible resource aids researchers in understanding cancer cell behavior during ICB treatment.
Area of Science:
- Immunology
- Oncology
- Bioinformatics
Background:
- Immune checkpoint blockade (ICB) therapies show promise for cancer treatment but have variable efficacy.
- Understanding cell-specific responses to ICB is crucial for improving treatment outcomes.
- Existing single-cell RNA sequencing (scRNA-seq) studies are often limited in scope and accessibility.
Purpose of the Study:
- To create a comprehensive, accessible resource of scRNA-seq data for investigating cancer cell responses to ICB.
- To facilitate cross-cancer type analysis of ICB treatment effects at the single-cell level.
- To lower the barrier for researchers exploring complex scRNA-seq datasets.
Main Methods:
- Compiled eight scRNA-seq datasets from nine cancer types, including 223 patients.
- Processed and analyzed data from over 90,000 cancer cells and 265,000 other cell types.
- Developed a user-friendly interface and shared code for data exploration.
Main Results:
- Established a large-scale, curated scRNA-seq resource for ICB research.
- Enabled investigation of cancer cell responses to ICB across diverse cancer types.
- Provided accessible tools and data for the research community.
Conclusions:
- This integrated scRNA-seq resource enhances the study of ICB treatment across multiple cancer types.
- The accessible platform and shared data empower researchers to explore ICB responses more effectively.
- Facilitates a deeper understanding of cancer cell heterogeneity and treatment sensitivity.
